FOSTER CITY, Calif.--(BUSINESS WIRE)--Applied Biosystems (NYSE: ABI), an Applera Corporation business, and its joint venture partner, Sciex, a division of MDS Inc.’s Analytical Technologies business, (NYSE:MDZ, TSX:MDS), today announced plans to commercialize a first-of-its-kind mass spectrometry platform designed to help pharmaceutical companies accelerate the drug compound screening process. The FlashQuantTM platform is expected to be the first commercially available system to combine industry-standard triple quadrupole mass spectrometry with widely-used MALDI technology. The expected result is an unparalleled level of speed in the process of drug compound screening. Laboratory tests conducted by Applied Biosystems/MDS SCIEX with the new platform have consistently delivered a 25-fold increase in speed for small molecule quantitation, compared with the fastest liquid chromatography-coupled triple quadrupole mass spectrometers currently in the market.
